Drug General Information
Drug ID	D01TCB
Former ID	DNCL001974
Drug Name	ELND005
Indication	Mild to moderate alzheimer disease [ICD9: 331; ICD10:G30]		Phase 2	[524184]
Company	Elan; Transition Therapeutics
Structure		Download 2D MOL 3D MOL
Target and Pathway
Target(s)	Amyloid beta A4 protein	Target Info	Modulator	[531622]
KEGG Pathway	Notch signaling pathway
	Alzheimer's disease
Reactome	Nuclear signaling by ERBB4
	Degradation of the extracellular matrix
	Regulated proteolysis of p75NTR
	NRIF signals cell death from the nucleus
	Activated NOTCH1 Transmits Signal to the Nucleus
	Constitutive Signaling by NOTCH1 PEST Domain Mutants
	Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
	EPH-ephrin mediated repulsion of cells
WikiPathways	Notch Signaling Pathway
	Signaling by ERBB4
	Signaling by NOTCH3
	Signaling by NOTCH4
	Signaling by NOTCH1
	Signaling by NOTCH2
	Notch Signaling Pathway
	Alzheimers Disease
	Signalling by NGF
References
Ref 524184	ClinicalTrials.gov (NCT01766336) A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease. U.S. National Institutes of Health.
Ref 531622	A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease. Neurology. 2011 Sep 27;77(13):1253-62.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.